On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge and insight regarding kidney disease. Dr. Humphreys reviewed chronic kidney disease and kidney injury as it relates to therapy with both […]
Dr. Benjamin D. Humphreys, GIST, Gleevec, imatinib, Kidney Toxicities, Long-Term GIST, sunitinib, sutent
On February 1, 2016, there was a commercial launch of the generic version of imatinib mesylate (Gleevec) which is approved for CML patients by the FDA. As the first to file for generic marketing in the US, Sun Pharmaceuticals was given a 6-month market exclusivity, and it has since expired in August 2016. There are […]
Apotex, generic imatinib, Gleevec, Sun Pharmaceuticals, TevaOn February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), originally for CML (Chronic Myeloid Leukemia), was approved by the FDA and became available for the first time in the United States through Sun Pharmaceuticals. In response to this transition, the LRG provided an educational Webinar to the CML and […]
generic imatinib, Generics, Gleevec, Novartis, Patient Education
A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy have better survival rates than those treated with surgery alone. Since the discovery of imatanib (Gleevec), treatment for gastrointestinal stromal […]
Adjuvant, GIST, Gleevec, imatinib